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Abstract
BACKGROUND & AIMS—Osteopenic bone disease occurs frequently among patients with
chronic liver disease but has not been well studied in those with primary sclerosing cholangitis
(PSC). We investigated the prevalence, rate of progression, and independent predictors of bone
disease in a large number of patients with all stages of PSC.
METHODS—Bone mineral density of the lumbar spine, hip, and total body was measured yearly
for 10 years in 237 patients with PSC.
RESULTS—Osteoporosis (t-score below –2.5) was found in 15% of patients and occurred 23.8-
fold (95% confidence interval [CI]: 4.6–122.8) more frequently in those with PSC than expected
from a matched population. By multivariate analysis, age ≥54 years (odds ratio [OR]=7.8, 95%
CI: 3.3–18.3], body mass index ≤24 (OR=4.9, 95% CI: 1.9–12.6), and inflammatory bowel
disease for ≥19 years (OR=3.6, 95% CI:1.5–8.4) correlated with the presence of osteoporosis.
Osteoporosis was present in 75% of patients with all 3 risk factors, but in only 3.1% of those
without all of them. Patients with PSC lost 1% of bone mass per year; this rate of bone loss was
significantly associated with duration of inflammatory bowel disease.
CONCLUSIONS—Osteoporosis occurs frequently among patients with PSC. Old age, low body
mass index, and long duration of inflammatory bowel disease can be used to identify patients with
PSC who might derive the most benefit from measurements of bone density and treatments for
bone diseases.
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Metabolic bone disease with its predisposition to fractures and bone pain occurs commonly
in patients with chronic liver disease of different causes.1 Bone disease has been studied
extensively in patients with chronic cholestatic liver disease such as primary biliary cirrhosis
(PBC).2 Primary sclerosing cholangitis (PSC) is another chronic cholestatic liver disease
that, unlike PBC, occurs at a younger age and affects mainly males.3 Most patients with
PSC also suffer from inflammatory bowel disease (IBD) which itself, particularly Crohn’s
disease significantly increases the risk of developing osteoporosis.4,5 This risk is even
greater in patients with IBD treated with corticosteroids.6 Bone disease in patients with
PSC, however, has remained largely unstudied.
In an early report, 15 out of 30 patients with PSC undergoing evaluation for liver
transplantation were found to have severe bone disease, but bone mass was normal in 18
patients studied with recently diagnosed PSC.7 Two more recent reports that included highly
selected patients with PSC found osteoporosis in 9% of patients at the time of enrollment in
a randomized trial of ursodeoxycholic8 and in a third of patients with end-stage PSC
evaluated for liver transplantation.9 In the early post-transplant period both the rate of bone
loss and the proportion of patients experiencing fractures increased substantially with low
bone mass in the pre-transplant period being one of the strongest predictors of post-
transplant fractures.10
Hence, larger studies with unselected patient populations are necessary to determine the real
prevalence of bone disease in patients with PSC, and to characterize those patients with
more severe bone disease. Furthermore, the identification of patients with bone disease pre-
liver transplantation would help in selecting those patients with PSC more apt to derive the
most benefit from enrollment in clinical trials and treatment of their bone disease. In
addition, a large study with long-term follow-up may potentially serve as the basis for future
guidelines regarding the frequency of bone density testing in patients with PSC. To deal
with these issues we conducted this longitudinal, cohort study designed 1) to determine the
prevalence and rate of progression of bone disease in a large number of patients with all
stages of PSC, and 2) to identify predictors of bone disease and progression.
MATERIAL AND METHODS
Patient Population
The bone mineral density (BMD) of the lumbar spine at L2-L4 was determined in 237
patients with cholangiography- and liver biopsy-confirmed PSC. These patients were seen at
the Mayo Clinic in Rochester, MN for the first time from 1/1/1991 to 12/31/1998. The date
of 1/1/91 was chosen because it was the date when the current normal values of bone density
measurement were established at the Mayo Clinic. Measurement of BMD was done at the
time of the first visit and, in most patients, repeated at annual intervals thereafter. BMD of
left femoral neck and total body was also measured in 48 and 60 patients, respectively.
The diagnosis of PSC was established based upon the following criteria: 1) chronic
cholestatic liver disease of at least 6 months’ duration with serum alkaline phosphatase
activity at least 1.5 times the upper limit of normal; 2) liver biopsy within 3 months
consistent with the diagnosis of PSC; 3) endoscopic and/or percutaneous cholangiography
showing the typical changes of PSC; and 4) appropriate exclusion of other liver diseases.
All patients had a complete medical history and physical examination performed at the time
of the first bone density measurement and at regular intervals thereafter. Information about
fractures was obtained both clinically and with radiographs taken at the lumbar and thoracic
spines and at the site of any bone pain. Body mass index (BMI) was calculated using the
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formula: BMI = weight in kilograms/(height in meters)2. Hematological and biochemical
parameters including hemoglobin, platelet count, prothrombin time, serum alkaline
phosphatase activity, and serum levels of total bilirubin, aspartate aminotransferase (AST),
albumin, calcium, phosphorus, creatinine, and vitamin D (total, 25-hydoxy, and 1,25
dihydroxy) were determined at the time of the first bone density measurement. Calcium
levels were corrected for albumin levels: 0.8 mg/dL of calcium were added for every 1.0 g/
dL that serum albumin fell below 4.0 g/dL. Esophagogastroduodenoscopy and
ultrasonography of the abdomen were also performed. The Mayo risk score was calculated
using the revised PSC score:11 Risk = 0.03 *age (years) + 0.54 *loge (total bilirubin [mg/
dL]) −0.84 *albumin (g/dL) + 0.54 * loge (AST [IU/L]) + 1.24 *variceal bleeding (yes = 1;
no = 0).
Colonoscopy and/or flexible sigmoidoscopy to assess for IBD were performed in all cases
and the diagnosis of IBD was confirmed histologically. The type of IBD was recorded and
cumulative lifetime prednisone dose until the date of the first bone density measurement was
calculated. Disease activity at the time of bone density measurement was determined using
the Truelove and Witts index for ulcerative colitis12 (index 6–19 means disease in
remission; index> 19 means active disease) and the Crohn’s disease activity index for
Crohn’s disease (index> 150 means active disease).13 Data on surgical resection of the colon
and the length of the resected small bowel were recorded in each patient. Duration of IBD
was determined as the time elapsed since the first clinical, endoscopic or histologic evidence
leading to the diagnosis of IBD until the time of the first bone density measurement.
Duration of PSC was determined as the time elapsed since the first clinical, biochemical or
cholangiographic findings leading to the diagnosis of PSC until the time of the first bone
density measurement.
A detailed review of drug history and drugs taken during follow-up were recorded. During
follow-up, budesonide was given to eight (3.4%) patients for treatment of PSC14 while
biphosphonates were given to 3 (1.3%) patients for treatment of bone disease. However, the
bone density measurements performed during and after treatment with these medications
were not included in any part of this analysis.
Bone Density Measurement
Bone mineral density (BMD) was measured by dual energy x-ray absorptiometry using
Hologic machines (measurements reproducibility of 2.2%). Bone mass was expressed in
absolute values (g/cm2), t-score (number of standard deviations compared with a young [30-
year old] adult sex-matched reference population), and z-score (number of standard
deviations compared with an age-and sex-matched reference population). As defined by the
World Health Organization, a t-score between −1 and −2.5 would indicate osteopenia, while
a t-score below −2.5 would indicate osteoporosis.15,16 A z-score below −2 would indicate a
value in the lowest 2.5th percentile of the reference range, a value associated with a
considerably larger increase in the risk of fracture.17
Matched Control Population
Bone density measurements were compared with the expected normal bone density adjusted
for age, sex, and ethnic group using standard values for normal United States population
provided by the Hologic reference database (Hologic, Inc; Waltham, MA)18,19 This
database contains nearly 1000 lumbar spine and over 1400 hip measurements performed in
healthy adult volunteers of either sex.18,19
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Statistical Analysis
Comparison of clinical, biochemical and histologic variables was done across t-scores and z-
scores. Results are expressed as mean ± SEM (range) and number (proportion) of patients
with a condition. The risk of having bone disease (t-score below −2.5; z-score below −2)
was calculated using the corresponding probability of the standard normal density, that is,
P(t < −2.5) or P(z < −2). Univariate analysis was performed using standard parametric (if
normally distributed) or non-parametric (if non-normally distributed) statistics for
comparison of continuous variables. The Chi-squared or Fisher’s Exact test, where
appropriate, was used for comparison of frequency data. The independent effect of
significant variables (p < 0.05) on the severity of bone disease was assessed using
multivariate logistic regression analysis with both the backward and forward stepwise
selection procedures. Receiver operating characteristics curve (ROC) were created to
identify the best cut-off value of independent predictors to distinguish between patients with
and without bone disease. Multivariate linear regression analysis was used to identify
independent predictors of the rate of progression of bone disease. The study was approved
by the Mayo Institutional Review Board and all patients had given informed consent for
participation in medical research.
RESULTS
Table 1 summarizes the demographic, clinical and biochemical data as well as the histologic
stage of disease of the patient population. The 237 patients, including 100 (42%) female and
137 (58%) male had a mean age of 45.5 ± 0.8 years (range 15–73). One-hundred seventy-
five (74%) patients had IBD including 142 (60%) patients with ulcerative colitis, 32 (13.4%)
with Crohn’s disease, and one (0.6%) patient with unclassified IBD. The bowel disease was
in remission in all patients at the time of the first bone density measurement. About a half of
patients had earlier (stage 1–2) disease, and 52 (22%) patients had cirrhotic-stage PSC.
Deficiency of vitamin D and calcium was found in 54 (23%) and 9 (4%) patients
respectively and corrected by oral supplementation. Prior fractures occurred in 14 (5.9%)
patients and, in all of them, the t-score was in the range of osteopenia or osteoporosis.
At baseline, the bone density of the lumbar spine correlated strongly with the bone density
of the hip (r = 0.65, P < 0.001) and with that of the total body (r = 0.78, P < 0.001). The
baseline bone density of the lumbar spine was significantly lower in PSC than expected in a
matched population of the same age and sex (0.97 ± 0.01 vs. 1.05 ± 0.004 g/cm2
respectively, p < 0.001) as was the t-score (−1.19 ± 0.09 vs. −0.43 ± 0.03 respectively, p <
0.001). There was no a significant difference between patient with and without IBD in terms
of baseline bone density (p=0.8), t-score (p=0.6), and z-score (p=0.3).
Prevalence of bone disease
A t-score below −2.5 (osteoporosis) of either the lumbar spine or femoral neck was found in
35 (15%) patients; this prevalence of osteoporosis was 23.8 times [95% confidence intervals
(CI) 4.6–122.8] higher in patients with PSC than expected in a young adult sex-matched
population. Ninety-seven (41%) patients had a t-score between −1 and −2.5 (osteopenia),
and 105 patients (44%) had a t-score above −1 (normal bone mass). Severe osteoporosis (z-
score below −2) of either the lumbar spine or femoral neck was found in 33 (14%) patients;
this prevalence of severe osteoporosis was 6.1 times (95% CI 2.5–14.9) higher in patients
with PSC than expected in an age- and sex-matched population.
Predictors of t-score
Table 1 summarizes the univariate analysis of the association of osteoporosis and potential
predictors. By multivariate analysis only age, BMI and duration of IBD were significantly
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associated with the presence of osteoporosis. Based on ROC curves the best threshold for
age was 54 years, for BMI was 24, and for duration of IBD was 19 years. Table 2
summarizes the odds ratio and 95% CI for the three factors independently associated with
osteoporosis. When age was excluded from the model, the menopausal status gained
statistical significance [odds ratio (OR) 4.04, 95% CI 1.44–11.34, P = 0.008]. Seventy-five
percent of patients 54 years or older who had a BMI equal to or less than 24 as well as 19
years or more of IBD duration had osteoporosis. However, only 3.1% of patients younger
than 54 years, with a BMI greater than 24 and less than 19 years of IBD duration had
osteoporosis (Figure 1). The presence of only one, or two of these three risk factors
predicted osteoporosis in 12.5% to 47% of our cohort.
Predictors of z-score
Table 1 summarizes the results of the univariate analysis of the association of severe
osteoporosis and potential predictors. By mutivariate analysis only BMI and duration of IBD
correlated significantly with the presence of severe osteoporosis (Table 3).
Rate of Progression of bone disease
One-hundred and eight (46%) patients were eligible for this part of the study. These patients
had a total of 568 bone densities of the lumbar spine, 88 of the femoral neck, and 126 of the
total body measured during a mean follow-up of 4.0 ± 0.2 years (range 1–10 years). The
remaining 129 patients had only the baseline bone density measurement. During follow-up,
the bone density of the lumbar spine correlated significantly with the bone density of the hip
in 88 paired measurements and with that of the total body in 126 paired measurements
(Figures 2A and 2B).
Patients with PSC lost bone mass at an average rate of −0.010 ± 0.002 g/cm2/year (range
−0.10 to 0.04 g/cm2/year), that is, an average of 1% bone mass per year (Figure 3). This rate
of bone loss was similar in the three bone sites evaluated (p = 0.7). This rate of bone loss in
PSC was significantly higher than the rate of bone loss expected in a matched population of
the same age and sex (−0.010 ± 0.002 vs. −0.004 ± 0.000 g/cm2/year, respectively, p =
0.03). The rate of bone loss in PSC was not significantly affected by vitamin D and/or
calcium supplementation (p = 0.5), use of corticosteroids (p = 0.2) or hormone replacement
therapy (p = 0.4). By univariate analysis duration of IBD, alkaline phosphatase, AST,
triglycerides and Mayo risk score were significantly associated with a greater rate of bone
loss. By multivarate analysis, however, the only variable that correlated significantly with
the rate of loss of bone mass was a longer duration of IBD (p = 0.02) even when hormone
replacement therapy, use of corticosteroids and vitamin D and calcium supplementation
were included in the model.
DISCUSSION
In this large series, we found that 15% of patients with PSC had established osteoporosis (t
score < −2.5) at the time of their first visit to our institution with a 23.8-fold increased risk
of osteoporosis. Fourteen percent had severe osteoporosis (z score < −2.0) at the time of first
visit with a 6.1-fold increased risk of severe osteoporosis. Using routinely determined
clinical, biochemical and histological variables we have shown that factors that
independently predict the presence of osteoporosis are advanced age, lower BMI and longer
duration of IBD. Patients with PSC lost bone mass at a rate of 1% per year and this rate of
bone loss over time seemed to be greatly influenced by the duration of IBD.
Our prior report on bone disease in PSC included only 81 patients, seven of whom had
osteoporosis, followed-up for a short period of time.8 As such, we were not able to perform
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robust multivariate analyses looking at predictors of bone disease and rate of bone loss in
PSC. In addition, since those patients were selected from participants enrolled in a clinical
trial of ursodeoxycholic acid, we were not able to determine a realistic estimate of the
prevalence and severity of bone disease in PSC.8 Hence, all conclusions in that study were
drawn on the basis of simple univariate comparison between patients with and without
severe bone disease. The current study is powered and designed to allow us to draw more
meaningful and reliable conclusions regarding bone disease in PSC.
Advanced age and lower BMI are well-known risk factors for the development of
osteoporosis in an otherwise healthy population as is menopausal status.20 Our findings of
the correlation between advanced age and lower BMI with osteoporosis in patients with PSC
may be related to similar pathophysiologic mechanisms which occur in the general
population. Osteoporosis is one of the few conditions in which excess body weight is
protective.21,22 Intriguing are recent results suggesting that the polypeptide hormone leptin
may modulate bone mass indirectly by a central effect.23 This finding may provide a
molecular explanation for the relationship between body weight and osteoporosis.
In our study, although menopausal status was not initially significant by multivariate
analysis, this variable was significant as an independent predictor of osteoporosis when age
was excluded from the model which indicates that the effect of menopausal status as an
independent predictor of osteoporosis is captured by age when both variables compete in the
model.
PSC is often referred as a disease affecting predominantly men; however, 42% of our cohort
were women which simply reflects the changes in the demographics of this disease over the
last four decades. For instance, the proportion of women with PSC seen in our institution
was only 30% in the 1970’s24 as compared with a proportion greater than 40% in the last
two decades (unpublished data). Interestingly, neither the severity of bone disease nor the
rate of boss loss was significantly affected by gender in our cohort.
The 15% prevalence of osteoporosis found in our patients with PSC is lower than the
prevalence of 20% to 37% reported in patients with PBC.25–28 In patients with PBC, older
age, lower BMI, menopausal status, and more advanced liver disease were independently
correlated with presence of osteoporosis.25,28 The exact pathogenic mechanism for
osteopenic bone disease in chronic cholestatic liver disease remains unknown, but
cholestasis on its own may contribute significantly to bone loss in patients with PSC and
PBC. Bilirubin has been shown to inhibit osteoblast function in vitro29 and this osteoblast
dysfunction may play a role in the low bone formation rate seen in cholestatic patients.
Higher serum bilirubin and other surrogate markers of disease severity such as albumin,
Mayo risk score and histologic stage of disease were significantly associated with the
presence of osteoporosis by univariate analysis in our patients with PSC. However, unlike
PBC the severity of liver disease as determined by these factors seemed to be of less
importance when these variables competed with age, BMI, duration of IBD and menopausal
status in a multivariate model. Intriguing are recent data demonstrating similar bone
histomorphometric changes in PSC and PBC suggesting that both decreased bone formation
and increased resorption contribute to bone disease in female patients with PSC or PBC,
whereas decreased bone formation rather than increased resorption may be an important
pathogenic mechanism in male patients with these conditions.30 These histomorphometric
studies were done in patients with advanced PSC and PBC undergoing liver transplantation,
30 and thus further studies are necessary to determine whether similar histomorphometric
changes occur in patients with earlier stages of liver disease.
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Treatment with corticosteroids is a well-known risk factor for development of osteoporosis
in patients with IBD.4,6 The use of corticosteroids in IBD is usually determined by the
severity of bowel symptoms. Hence, an intriguing observation in our study is the lack of
correlation between lifetime cumulative dose or use of corticosteroids and severity of bone
disease. This may be explained by the fact that IBD associated with PSC generally follows a
more quiescent course than in patients without PSC and hence, the lifetime dose of
corticosteroids for the treatment of IBD in PSC may be lower than in patients without
underlying PSC.31 In fact, only 25% of our patients required corticosteroid therapy at some
point (20% for the treatment of IBD); this proportion is much lower than that reported in
patients with IBD without PSC31–33 Hence, although corticosteroids are not recommended
for the treatment of PSC, the use of corticosteroids for the treatment of IBD seems to be
necessary in only a small proportion of patients with PSC, and this may explain the lack of
significant detrimental effects of corticosteroids on bone mass in our cohort of patients with
PSC. The longer duration of IBD which correlated significantly with severity of bone
disease and was the only factor independently associated with a greater bone loss over time,
may be the most important factor affecting bone mass in patients with PSC also suffering
from IBD.
Also, patients with IBD may have low bone mass at presentation before commencement of
corticosteroids.4 The role of inflammatory cytokines such as interleukin 1 and 6 and tumor
necrosis factor in promoting increased bone resorption and decreased bone formation may
be one of the critical factors leading to bone disease in patients with IBD34 as is vitamin D
defiency35 regardless of corticosteroid use. In addition, vitamin K has been implicated in
promoting bone health in the post-menopausal state, and in a number of clinical conditions
associated with bone loss including primary biliary cirrhosis.36,37 However, further studies
are necessary to determine both the association of bone disease and vitamin K deficiency in
patients with PSC, and what therapeutic effects vitamin K may have in the bone disease in
patients with PSC.
It remains uncertain when and how often the bone density measurement needs to be repeated
in patients with PSC. Our data can serve as the basis for guidelines regarding the frequency
of BMD testing in these patients. Since more than half of patients with PSC present with a t-
score in the range of osteopenia or osteoporosis it seems reasonable to measure the bone
density in all patients at the time of diagnosis of PSC. Patients with PSC lose bone mass at
an average of 1% per year; this rate of bone loss along with duration of IBD (i.e., the only
independent predictor of higher rate of bone loss) should be considered when deciding the
frequency of subsequent bone density measurement. For those patients with normal bone
mass and short duration of IBD, repeating the BMD every 2 to 3 years seems appropriate.
However, repeating the BMD at annual or semiannual intervals seems to be appropriate for
those patients with bone mass in the range of osteopenia, particularly those with long-lasting
IBD; this would allow the early identification and more aggressive management of the bone
disease in those patients progressing to osteoporosis.
There are no data on prevention and treatment of bone disease in patients with PSC.
However, general recommendations such as supportive measurements for bone health (i.e.,
increased physical exercise, and quit alcohol and smoking), and assuring a diet with
appropriate content of calcium and vitamin D, or their supplementation if deficient, can be
implemented in patients with PSC.38 Similarly, there are no data regarding the appropriate
time to start treatment for the bone disease in patients with PSC; but patients with
established osteoporosis and those who had experienced a fragility fracture should be treated
to reduce the risk of further fractures as recommended in the general population.39 In
addition, since all fragility fractures in our cohort occurred with a t-score < −1.5, it seems
reasonable to consider treatment in patients with PSC and BMD below this threshold,
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particularly if they have the risk factors for osteoporosis identified in this study, or if they
are on the waiting list for liver transplantation as a significant increment in the risk of
fragility fractures is expected in the post-transplant period.10 Although no controlled trials
have been reported in PSC, some medications including bisphosphonates, hormone
replacement therapy, and selective estrogen receptor modulators, have been evaluated for
the treatment of bone disease in patients with PBC,40–43 and in the liver transplant setting.
44–46 These medications seemed relatively efficacious and safe that they are often used to
treat the bone disease in PSC, but data from controlled trials in PSC are needed.
In summary, osteoporosis occurs commonly in patients with PSC. Longer duration of lBD
contributes significantly to the severity and rate of progression of bone disease and this
effect seems to be independent of other risk factors identified previously in the general
population. Our results show that older age, lower BMI and longer duration of IBD help
identify the subgroup of patients with PSC with more severe bone disease. This subset of
patients would be expected to derive the most benefit from serial measurements of bone
density, from adherence to medical therapy and from being enrolled in clinical trials aimed
at treating and preventing their bone loss.
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FIGURE 1.
Decision tree using the three variables (age, body mass index, and duration of IBD)
identified by multivariate analysis. The term osteoporosis refers to a t-score below −2.5
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FIGURE 2.
Correlation of bone mineral density of the lumbar spine (L2-L4) with (A) bone mineral
density of femoral neck, and (B) bone mineral density of total body.
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FIGURE 3.
Bone mineral density of the lumbar spine (L2-L4) at baseline and at annual intervals. The
continuous line refers to mean and the discontinuous line refers to standard error of the
mean.
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Table 2
Multivariate analysis of the association between osteoporosis (T-score < −2.5) and independent predictors
Odds Ratio
95% Confidence Intervals
P valueLower Upper
Age (years)
 < 54 1
 ≥ 54 7.8 3.3 18.3 < 0.001
Body mass index
 > 24 1
 ≤ 24 4.9 1.9 12.6 0.001
Duration of IBD (years)
 < 19 1
 ≥ 19 3.6 1.5 8.4 0.004
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Table 3
Multivariate analysis of the association between severe osteoporosis (Z-score < −2.0) and independent
predictors
Odds Ratio
95% Confidence Intervals
P valueLower Upper
Body mass index
 > 24 1
 ≤ 24 7.5 2.0 27.7 0.003
Duration of IBD (years)
 < 19 1
 ≥ 19 3.7 1.3 10.1 0.01
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